Surface-Modified Bilosomes Nanogel Bearing a Natural Plant Alkaloid for Safe Management of Rheumatoid Arthritis Inflammation

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Mar 26

PMID 35335939

Authors

Mohammed H Elkomy

Nabil K Alruwaili

Mohammed Elmowafy

Khaled Shalaby

Ameeduzzafar Zafar

Naveed Ahmad

Izzeddin Alsalahat

Mohammed M Ghoneim

Essam M Eissa

Hussein M Eid

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory illness affecting the joints. The characteristic of RA is gradual joint deterioration. Current RA treatment alleviates signs such as inflammation and pain and substantially slows the progression of the disease. In this study, we aimed to boost the transdermal delivery of berberine (a natural product) by encapsulating it in chitosan, surface-modified bilosomes nanogel for better management of the inflammation of RA. The chitosan-coated bilosomes loaded with berberine (BER-CTS-BLS) were formulated according to the thin-film hydration approach and optimized for various causal variables, considering the effect of lipid, sodium deoxycholate, and chitosan concentrations on the size of the particles, entrapment, and the surface charge. The optimized BER-CTS-BLS has 202.3 nm mean diameter, 83.8% entrapment, and 30.8 mV surface charge. The optimized BER-CTS-BLS exhibited a delayed-release profile in vitro and increased skin permeability ex vivo. Additionally, histological examination revealed that the formulated BLS had no irritating effects on the skin. Furthermore, the optimized BER-CTS-BLS ability to reduce inflammation was evaluated in rats with carrageenan-induced paw edema. Our results demonstrate that the group treated with topical BER-CTS-BLS gel exhibited a dramatic reduction in rat paw edema swelling percentage to reach 24.4% after 12 h, which was substantially lower than other groups. Collectively, chitosan-coated bilosomes containing berberine have emerged as a promising therapeutic approach to control RA inflammation.

Citing Articles

The Pharmaceutical and Pharmacological Potential Applications of Bilosomes as Nanocarriers for Drug Delivery.

Mitrovic D, Zaklan D, danic M, Stanimirov B, Stankov K, Al-Salami H Molecules. 2025; 30(5).

PMID: 40076403 PMC: 11901966. DOI: 10.3390/molecules30051181.

Enhanced bioavailability of Quercetin-loaded niosomal in situ gel for the management of Parkinson's disease.

Revankar A, Patil A, Karishetti R, Chougule K, Patil P, Salokhe A Front Pharmacol. 2025; 15:1519649.

PMID: 39931515 PMC: 11808128. DOI: 10.3389/fphar.2024.1519649.

Intranasal trimethyl chitosan-coated emulsomes containing tizanidine as brain-targeted therapy in spasticity: formulation, optimization, and pharmacokinetic assessment.

Elkomy M, Hendawy O, Zaki R, Tulbah A, Aldosari B, Ali A Drug Deliv Transl Res. 2024; .

PMID: 39666261 DOI: 10.1007/s13346-024-01753-0.

Plant-Based Nanovesicular Gel Formulations Applied to Skin for Ameliorating the Anti-Inflammatory Efficiency.

Atia H, Shahien M, Ibrahim S, Haridy Ahmed E, Elariny H, Abdallah M Gels. 2024; 10(8).

PMID: 39195054 PMC: 11353947. DOI: 10.3390/gels10080525.

Neuroprotective efficiency of celecoxib vesicular bilosomes for the management of lipopolysaccharide-induced Alzheimer in mice employing 2 full factorial design.

Darwish A, Salama A, Younis M Inflammopharmacology. 2024; 32(6):3925-3942.

PMID: 39017993 PMC: 11550292. DOI: 10.1007/s10787-024-01522-y.

References

Hasanovic A, Hollick C, Fischinger K, Valenta C . Improvement in physicochemical parameters of DPPC liposomes and increase in skin permeation of aciclovir and minoxidil by the addition of cationic polymers. Eur J Pharm Biopharm. 2010; 75(2):148-53. DOI: 10.1016/j.ejpb.2010.03.014. View

Salama H, Mahmoud A, Kamel A, Hady M, Awad G . Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res. 2012; 22(4):336-45. DOI: 10.3109/08982104.2012.700460. View

Gibis M, Ruedt C, Weiss J . In vitro release of grape-seed polyphenols encapsulated from uncoated and chitosan-coated liposomes. Food Res Int. 2017; 88(Pt A):105-113. DOI: 10.1016/j.foodres.2016.02.010. View

Morris C . Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol. 2003; 225:115-21. DOI: 10.1385/1-59259-374-7:115. View

Avadhani K, Manikkath J, Tiwari M, Chandrasekhar M, Godavarthi A, Vidya S . Skin delivery of epigallocatechin-3-gallate (EGCG) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in UV radiation induced skin damage. Drug Deliv. 2017; 24(1):61-74. PMC: 8253143. DOI: 10.1080/10717544.2016.1228718. View

Hu Z, Jiao Q, Ding J, Liu F, Liu R, Shan L . Berberine induces dendritic cell apoptosis and has therapeutic potential for rheumatoid arthritis. Arthritis Rheum. 2010; 63(4):949-59. DOI: 10.1002/art.30202. View

Elkomy M, Elmenshawe S, Eid H, Ali A . Topical ketoprofen nanogel: artificial neural network optimization, clustered bootstrap validation, and in vivo activity evaluation based on longitudinal dose response modeling. Drug Deliv. 2016; 23(9):3294-3306. DOI: 10.1080/10717544.2016.1176086. View

Dora C, Singh S, Kumar S, Datusalia A, Deep A . Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm. 2010; 67(3):283-90. View

Elkomy M, El Menshawe S, Eid H, Ali A . Development of a nanogel formulation for transdermal delivery of tenoxicam: a pharmacokinetic-pharmacodynamic modeling approach for quantitative prediction of skin absorption. Drug Dev Ind Pharm. 2016; 43(4):531-544. DOI: 10.1080/03639045.2016.1268153. View

10.

Feist E, Burmester G . Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013; 52(8):1352-7. DOI: 10.1093/rheumatology/kes417. View

11.

Abdelbary A, Abd-Elsalam W, Al-Mahallawi A . Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: In vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm. 2016; 513(1-2):688-696. DOI: 10.1016/j.ijpharm.2016.10.006. View

12.

Honeywell-Nguyen P, Bouwstra J . Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol. 2014; 2(1):67-74. DOI: 10.1016/j.ddtec.2005.05.003. View

13.

Fan X, Leung E, Xie Y, Liu Z, Zheng Y, Yao X . Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases. Antioxid Redox Signal. 2017; 28(5):339-357. DOI: 10.1089/ars.2017.7090. View

14.

Niu M, Tan Y, Guan P, Hovgaard L, Lu Y, Qi J . Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2013; 460(1-2):119-30. DOI: 10.1016/j.ijpharm.2013.11.028. View

15.

Li L, Zhang Y, Han S, Qu Z, Zhao J, Chen Y . Penetration enhancement of lidocaine hydrochlorid by a novel chitosan coated elastic liposome for transdermal drug delivery. J Biomed Nanotechnol. 2011; 7(5):704-13. DOI: 10.1166/jbn.2011.1333. View

16.

Taveira S, Nomizo A, Lopez R . Effect of the iontophoresis of a chitosan gel on doxorubicin skin penetration and cytotoxicity. J Control Release. 2008; 134(1):35-40. DOI: 10.1016/j.jconrel.2008.11.002. View

17.

Khalil R, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy H . Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. J Liposome Res. 2018; 29(2):171-182. DOI: 10.1080/08982104.2018.1524482. View

18.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

19.

Panda D, Eid H, Elkomy M, Khames A, Hassan R, Abo El-Ela F . Berberine Encapsulated Lecithin-Chitosan Nanoparticles as Innovative Wound Healing Agent in Type II Diabetes. Pharmaceutics. 2021; 13(8). PMC: 8401853. DOI: 10.3390/pharmaceutics13081197. View

20.

Al-Mahallawi A, Abdelbary A, Aburahma M . Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. Int J Pharm. 2015; 485(1-2):329-40. DOI: 10.1016/j.ijpharm.2015.03.033. View